Dr Klaus Maleck

Dr Klaus Maleck joined the Evotec Management Board in April 2007 and became CFO in November 2007. From August 2010, he assumed responsibility for corporate development, focusing on M&A, strategy and licensing. Prior to Evotec, he built up BioGeneriX AG, which he co-founded in 2000. In his function as Chief Financial Officer and Vice President Business Development, he was responsible for in-licensing advanced development candidates and for building a product pipeline of up to six clinical development programs and several non-clinical projects, including two product approvals. He secured financing through extensive partnering and closed several co-marketing deals with big pharma, and thus was able to considerably increase the shareholder value. Dr Maleck worked as a Senior Consultant at McKinsey & Co. from 1999 to 2000, and as a Scientist in the genomics field at Novartis, Inc. from 1996 to 1999. He is also a lecturer at the Mannheim University in Economics. Dr Maleck is Chairman of Supervisory Board of the European Screening Port.

Dr Maleck received his Ph.D. in biotechnology from the Max-Planck-Insitute Cologne, and holds a Masters degree in biotechnology of the Ecole Supérieure de Biotechnologie in Strasbourg France. In addition, he received post-graduate training in economics at Ashridge College in the UK, and at Swiss-based Educatis University, where he earned an MBA degree. He was a fellow of the Conseil Régional d'Alsace, the Daimler-Benz-Foundation and the German Scholarship Foundation.